Cardiometabolic risk in Canada: A detailed analysis and position paper by the Cardiometabolic risk working group

Canadian Journal of Cardiology

Volumn 27, Issue 2, 2011, Pages

  Leiter, Lawrence A ^a,b   Fitchett, David H ^a,b   Gilbert, Richard E ^a,b   Gupta, Milan ^a,b,c,d   Mancini, G B John ^e   McFarlane, Philip A ^a,b   Ross, Robert ^f   Teoh, Hwee ^a   Verma, Subodh ^a,b   Anand, Sonia ^d   Camelon, Kathryn ^g   Chow, Chi Ming ^a,b   Cox, Jafna L ^h   Després, Jean Pierre ⁱ   Genest, Jacques ^j   Harris, Stewart B ^k   Lau, David C W ⁱ   Lewanczuk, Richard ^m   Liu, Peter P ^b,e   Lonn, Eva M ^e   McPherson, Ruth ⁿ   Poirier, Paul ^h   Qaadri, Shafiq ^o   Rabasa Lhoret, Rémi ^p   Rabkin, Simon W ^e   Sharma, Arya M ^m   Steele, Andrew W ^q   Stone, James A ^l   Tardif, Jean Claude ^r   Tobe, Sheldon ^b,s   Ur, Ehud ^e   more..

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c University of Queensland   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ UNIVERSITÉ LAVAL   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

^m UNIVERSITY OF ALBERTA   (Canada)

ⁿ UNIVERSITY OF OTTAWA   (Canada)

^o Institut de Recherches Cliniques de Montréal ^*

^p CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^q LAKERIDGE HEALTH CORPORATION   (Canada)

^r UNIVERSITÉ DE MONTRÉAL   (Canada)

^s SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ADIPOCYTOKINE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LISINOPRIL; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MEVINOLIN; NATEGLINIDE; PIOGLITAZONE; RAMIPRIL; RENIN INHIBITOR; ROSIGLITAZONE; ROSUVASTATIN; SIBUTRAMINE; SODIUM; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ABDOMINAL OBESITY; ADIPOCYTE; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; BARIATRIC SURGERY; BODY MASS; CALORIC RESTRICTION; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONSENSUS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EPIDEMIC; ETHNIC GROUP; EVIDENCE BASED MEDICINE; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HEART INFARCTION; HEART SURGERY; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; LIFESTYLE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPOLYSIS; META ANALYSIS; METABOLIC SYNDROME X; MORBID OBESITY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PHYSICIAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; STROKE; TREATMENT INDICATION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION; PRACTICE GUIDELINE; REVIEW;

CANADA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 79960769731     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.12.054     Document Type: Article

References (282)

1. Leiter LA, Fitchett DH, Gilbert GE, et al; for the Cardiometabolic Risk Working Group. Identification and management of cardiometabolic risk in Canada: A position paper by the Cardiometabolic Working Group [Executive Summary]. Can J Cardiol: in press
2. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006;113: 2943-46.
3. Kahn R, Buse J, Ferrannini E, Stern M; for the American Diabetes Association and the European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
4. Després J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.
5. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-22.
6. Després J-P, Cartier A, Côté M, Arsenault BJ. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med 2008;40:514-23.
7. Després J-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J Suppl 2006;8(suppl B):B4-12.
8. Reaven GM. Banting lecture 1998. Role of insulin resistance in human disease. Diabetes 1998;37:1595-607.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
11. Grundy SM, Cleeman JI, Daniels SR, et al; for the American Heart Association and the National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
12. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels, Belgium: International DiabetesFederation,; 2006.Available at:http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf. Accessed September 16, 2010.
13. Daly CA, Hildebrandt P, Bertrand M, et al; for the EUROPA investigators. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart 2007; 93:1406-11.
14. Mellen PB, Cefalu WT, Herrington DM. Diabetes, the metabolic syndrome, and angiographic progression of coronary arterial disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2006;26:189-93.
15. Nilsson PM, Engström G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects: a population-based study comparing three different definitions. Diabet Med 2007;24:464-72.
16. Nilsson PM. Cardiovascular risk in the metabolic syndrome: fact or fiction? Curr Cardiol Rep 2007;9:479-85.
17. Galassi A, Reynolds K, He J. Metabolic syndrome and the risk of cardiovascular disease: a meta-analysis. Am J Med 2006;119:812-19.
18. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and metaanalysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-14.
19. Noto D, Barbagallo CM, Cefalù AB, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis 2008;197:147-53.
20. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program: Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8-13.
21. de Simone G, Devereux RB, Chinali M, et al; for the Strong Heart Study Investigators. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 2007;30:1851-6.
22. Arnlov J, Ingelsson E, Sundstrom J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010;121:230-6.
23. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
24. Paras E, Mancini GB, Lear SA. The relationship of three common definitions of the metabolic syndrome with subclinical carotid atherosclerosis. Atherosclerosis 2008;198:228-36.
25. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010; 55:1169-77.
26. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-15.
27. Borch-Johnsen, Wareham N. The rise and fall of the metabolic syndrome. Diabetologia 2010;53:507-9.
28. Simmons RK, Alberti KGMM, Gale EAM, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010;53:600-5.
29. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res 2007;4:32-8.
30. Mente A, Yusuf S, Islam S, et al. Metabolic syndrome and risk of acute myocardial infarction: a case-control study of 26 903 subjects from 52 countries. J Am Coll Cardiol 2010;55:2390-8.
31. Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007;28:857-64.
32. International Chair on Cardiometabolic Risk. (Version current at September 16, 2010).
33. Saely CH, Rein P, Drexel H. The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the International Diabetes Federation. Horm Metab Res 2007;39:642-50.
34. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006;92:1752-9.
35. Simons LA, Simons J, Friedlander Y, McCallum J. Does a diagnosis of the metabolic syndrome provide additional prediction of cardiovascular disease and total mortality in the elderly? The Dubbo Study. Med J Aust 2007;186:400-3.
36. Hunt KJ, Williams K, Hazuda HP, Stern MP, Haffner SM. The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: the San Antonio Heart Study. Ann Epidemiol 2007;17:870-7.
37. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis 2008;197:392-9.
38. Tong PC, Kong AP, So WY, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007;30:1206-11.
39. Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J 2007;5:91-6.
40. Onat A, Can G, Hergenç G, Yazici M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes (Lond) 2007;31: 1119-25.
41. Lind L, Vessby B, Sundström J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006; 26:406-10.
42. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
43. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97(2A):3A-11A.
44. Saely CH, Marte T, Drexel H. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2004;350:1150-2.
45. Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley PG. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol 2005;46:807-14.
46. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300: 197-208.
47. Wyman RA, Mays ME, McBride PE, Stein JH. Ultrasound-detected carotid plaque as a predictor of cardiovascular events. Vasc Med 2006; 11:123-30.
48. Junyent M, Zambón D, Gilabert R, Núñez I, Cofán M, Ros E. Carotid atherosclerosis and vascular age in the assessment of coronary heart disease risk beyond the Framingham Risk Score. Atherosclerosis 2008;196: 803-9.
49. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010;3;55:1600-7.
50. Gepner AD, Keevil JG, Wyman RA, et al. Use of carotid intima-media thickness and vascular age to modify cardiovascular risk prediction. J Am Soc Echocardiogr 2006;19:1170-4.
51. Simmons RK, Sharp S, Boekholdt SM, et al. Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 2008;168:1209-16.
52. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 2008;101(12A):23F-33F.
53. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
54. Arnold JM, Liu P, Demers C, et al; Canadian Cardiovascular Society. Canadian Cardiovascular Society consensus recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006;22:23-45.
55. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47suppl 8):C19-31.
56. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791-8.
57. Daskalopoulou SS, Athyros VG, Kolovou GD, Anagnostopoulou KK, Mikhailidis DP. Definitions of metabolic syndrome: Where are we now? Curr Vasc Pharmacol 2006;4(3):185-97.
58. Lawlor DA, Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? findings from the British Women's Heart and Health Study. Diabetologia 2006;49:41-8.
59. Després J-P, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arteroscler Thromb Vasc Biol 2008;28:1039-49.
60. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? outcome data from two prospective studies. Lancet 2008;371:1927-35.
61. Sattar N. The metabolic syndrome: should current criteria influence clinical practice? Curr Opin Lipidol 2006;17:404-11.
62. American Diabetes Association. Understanding Cardiometabolic Risk: Broadening Risk Assessment and Management. Alexandria, VA: American Diabetes Association, 2007.
63. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
64. Rome S, Clément K, Rabasa-Lhoret R, et al. Microarray profiling of human skeletal muscle reveals that insulin regulates approximately 800 genes during a hyperinsulinemic clamp. J Biol Chem 2003;278: 18063-8.
65. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
66. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288(5):H2031-41.
67. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007; 292(4):H1655-63.
68. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilatation. J Clin Invest 1997;100:1230-9.
69. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase Cdependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000;49:1939-45.
70. Brownlee M. Biochemistry and molecular biology of diabetic complications. Nature 2001;414:813-20.
71. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces oxidative stress in healthy subjects. J Clin Invest 2001;108:635-6.
72. Kohler HP, Grant PJ. Plasminogen activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801.
73. Meugnier E, Faraj M, Rome S, et al. Acute hyperglycemia induces a global downregulation of gene expression in adipose tissue and skeletal muscle of healthy subjects. Diabetes 2007;56:992-9.
74. Prentki M, Madiraju SR. Glycerolipid metabolism and signaling in health and disease. Endocr Rev 2008;29:647-76.
75. Bravata DM, Wells CK, Concato J, Kernan WN, Brass LM, Gulanski BI. Two measures of insulin sensitivity provided similar information in a U.S. population. J Clin Epidemiol 2004;57:1214-7.
76. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normalweight Americans: new definition of the metabolically obese, normalweight individual. Diabetes Care 2004;27:2222-8.
77. Mayer-Davis EJ, D'Agostino R Jr, Karter AJ, et al. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance Atherosclerosis Study. JAMA 1998;279:669-74.
78. Vessby B, Unsitupa M, Hermansen K, et al; KANWU study group. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia 2001;44:312-9.
79. Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005;90:4145-50.
80. Conus F, Rabasa-Lhoret R, Péronnet F. Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab 2007;32:4-12.
81. Després J-P, Tchernof A. Classification of overweight and obesity. In: 2006 Canadian clinical practice guidelines on management and prevention of obesity in adults and children. CMAJ 2007;176:Online 21-26. Available at http://www.cmaj.ca/cgi/data/176/8/S1/DC1/1. Accessed January 29, 2011.
82. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després J-P. Visceral obesity and the heart. Int J Biochem Cell Biol 2008;40:821-36.
83. Poirier P. Healthy lifestyle: even if you are doing everything right, extra weight carries an excess risk of acute coronary events. Circulation 2008; 117;3057-9.
84. Poirier P, Eckel RH. Cardiovascular consequences of obesity. Drug Discov Today: Ther Strategies 2008:5:45-51.
85. Poirier P, Lemieux I, Mauriège P, et al. Impact of waist circumference on the relationship between blood pressure and insulin. The Quebec Health Survey. Hypertension 2005;45:363-7.
86. Health Canada. Canadian Guidelines for Body Weight Classification in Adults; 2003. Ottawa, ON: Health Canada, Publication H49-179/2003E.
87. Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation 2009;120: 86-95.
88. Ross R, Berentzen T, Bradshaw AJ, et al. Does the relationship between waist circumference, morbidity and mortality depend on measurement protocol for waist circumference? Obesity Rev 2008;9:312-25.
89. National Institutes of Health. The Practical Guide to the Identification, Evaluation and Treatment of Overweight and Obesity in Adults; 2000. Bethesda, MD, National Institutes of Health, NIH publication no. 00-4084.
90. Canadian Education Hypertension Education Program. 2010 Canadian Education Hypertension Education Program recommendations: the short clinical summary: an annual update. Available at: http://hypertension.ca/chep/wp-content/uploads/2010/02/ShortClinicalSummary_2010.pdf. Accessed September 16, 2010.
91. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354: 1685-97.
92. Canadian Institute For Health Information. 2007 Annual Report: Treatment of End-Stage Organ Failure in Canada, 1996 to 2005. Ottawa: Canadian Institute For Health Information, 2008.
93. Reenders K, de Nobel E, van den Hoogen HJ, Rutten GE, van Weel C. Diabetes and its long-term complications in general practice: a survey in a well-defined population. Fam Pract 1993;10:169-172.
94. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005;165:923-8.
95. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-92.
96. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.
97. Simon N, Franklin SS, Bleifer KH, Maxwell MH. Clinical characteristics of renovascular hypertension. JAMA 1972;220:1209-18.
98. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(suppl 1):S1-201.
99. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-79.
100. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-6.
101. Lau DC, Douketis JD, Morrison KM, et al; for the Obesity Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007;176(8):S1-13.
102. Janiszewski PM, Ross R. Physical activity in the treatment of obesity: beyond body weight reduction. Appl Physiol Nutr Metab 2007;32: 512-22.
103. Ross R, Janssen I, Dawson J, et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes Res 2004;12:789-98.
104. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men: a randomized, controlled trial. Ann Intern Med 2000;133:92-103.
105. Irwin ML, Yasui Y, Ulrich CM, et al. Effect of exercise on total and intra-abdominal body fat in postmenopausal women: a randomized controlled trial. JAMA 2003;289:323-30.
106. DiPietro L, Dziura J, Yeckel CW, Neufer PD. Exercise and improved insulin sensitivity in older women: evidence of the enduring benefits of higher intensity training. J Appl Physiol 2006;100:142-9.
107. Ross R, Janssen I. Physical activity, total and regional obesity: doseresponse considerations. Med Sci Sports Exerc 2001;33(suppl 6): S521-7.
108. Green JS, Stanforth PR, Rankinen T, et al. The effects of exercise training on abdominal visceral fat, body composition, and indicators of the metabolic syndrome in postmenopausal women with and without estrogen replacement therapy: the HERITAGE family study. Metabolism 2004;53:1192-6.
109. Ross RB, Bradshaw AJ. The future of obesity reduction: beyond weight loss. Nature Rev Endocrinol 2009;5:319-25.
110. Han TS, Richmond P, Avenell A, Lean ME. Waist circumference reduction and cardiovascular benefits during weight loss in women. Int J Obes Relat Metab Disord 1997;21:127-34.
111. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005;293:43-53.
112. Cox KL, Burke V, Morton AR, Beilin LJ, Puddey IB. The independent and combined effects of 16 weeks of vigorous exercise and energy restriction on body mass and composition in free-living overweight men - a randomized controlled trial. Metabolism 2003;52:107-15.
113. Sönnichsen AC, Richter WO, Schwandt P. Benefit from hypocaloric diet in obese men depends on the extent of weight-loss regarding cholesterol, and on a simultaneous change in body fat distribution regarding insulin sensitivity and glucose tolerance. Metabolism 1992;41:1035-9.
114. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999;48:839-47.
115. Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 2000;85:977-82.
116. Larson-Meyer DE, Heilbronn LK, Redman LM, et al. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell func tion, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006;29:1337-44.
117. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. The Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults: The Evidence Report; 1998. Rockland, MD: US Department of Health and Human Services, NIH Publication No. 98-4083.
118. Larsen JJ, Dela F, Kjaer M, Galbo H. The effect of moderate exercise on postprandial glucose homeostasis in NIDDM patients. Diabetologia 1997;40:447-53.
119. Musi N, Fujii N, Hirshman MF, et al. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 2001;50:921-7.
120. Thompson PD, Crouse SF, Goodpaster B, Kelley D, Moyna N, Pescatello L. The acute versus the chronic response to exercise. Med Sci Sports Exerc 2001;33:S438-45.
121. Burstein R, Epstein Y, Shapiro Y, Charuzi I, Karnieli E. Effect of an acute bout of exercise on glucose disposal in human obesity. J Appl Physiol 1990;69:299-304.
122. Perseghin G, Price TB, Petersen KF, et al. Increased glucose transportphosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996;335:1357-62.
123. Devlin JT, Hirshman M, Horton ED, Horton ES. Enhanced peripheral and splanchnic insulin sensitivity in NIDDM men after single bout of exercise. Diabetes 1987;36:434-9.
124. Mikines KJ, Sonne B, Farrell PA, Tronier B, Galbo H. Effect of physical exercise on sensitivity and responsiveness to insulin in humans. Am J Physiol 1988;254:E248-59.
125. Laaksonen DE, Atalay M, Niskanen LK, et al. Aerobic exercise and the lipid profile in type 1 diabetic men: a randomized controlled trial. Med Sci Sports Exerc 2000;32:1541-8.
126. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
127. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
128. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9.
129. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993;77:1287-93.
130. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
131. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94.
132. DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
133. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010;376:103-11.
134. DeFronzo R. ACTosNOWfor the prevention of diabetes (ACT NOW) study. Oral presentation at: American Diabetes Association 68th Scientific Sessions. June 9, 2008; San Francisco, CA.
135. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
136. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374-83.
137. Stefanick ML. Physical activity for preventing and treating obesity-related dyslipoproteinemias. Med Sci Sports Exerc 1999;31(suppl 11): S609-18.
138. Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL, DuBose KD. Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports Med 2001;31:1033-62.
139. Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc 2001; 33(suppl 6):S502-15.
140. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sports Med 2004;34:371-418.
141. Halbert JA, Silagy CA, Finucane P, Withers RT, Hamdorf PA. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 1999; 53:514-22.
142. Ballantyne FC, Clark RS, Simpson HS, Ballantyne D. The effect of moderate physical exercise on the plasma lipoprotein subfractions of male survivors of myocardial infarction. Circulation 1982;65:913-8.
143. Stubbe I, Hansson P, Gustafson A, Nilsson-Ehle P. Plasma lipoproteins and lipolytic enzyme activities during endurance training in sedentary men: changes in high-density lipoprotein subfractions and composition. Metabolism 1983;32:1120-8.
144. Kodama S, Tanaka, S, Saito, K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007;167:999-1008.
145. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75.
146. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002;347: 1483-92.
147. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992;56:320-8.
148. Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004;89:2697-703.
149. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002;136:493-503.
150. Kelley GA. Effects of aerobic exercise in normotensive adults: a brief meta-analytic review of controlled clinical trials. South Med J 1995;88: 42-6.
151. Kelley GA. Aerobic exercise and resting blood pressure among women: a meta-analysis. Prev Med 1999;28:264-75.
152. Arroll B, Beaglehole R. Does physical activity lower blood pressure: a critical review of the clinical trials. J Clin Epidemiol 1992;45:439-47.
153. Hagberg JM, Park JJ, Brown MD. The role of exercise training in the treatment of hypertension: an update. Sports Med 2000;30:193-206.
154. Fagard RH. Physical activity in the prevention and treatment of hypertension in the obese. Med Sci Sports Exerc 1999;31(suppl 11):S624-30.
155. Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension 2005;46:667-75.
156. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;42:878-84.
157. Fagard RH. Effects of exercise, diet and their combination on blood pressure. J Hum Hypertens 2005;19(suppl 3):S20-4.
158. Eriksson J, Taimela S, Koivisto VA. Exercise and the metabolic syndrome. Diabetologia 1997;40:125-35.
159. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701-9.
160. Feldeisen SE, Tucker KL. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab 2007;32: 46-60.
161. Grundy SM, Abate N, Chandalia M. Diet composition and the metabolic syndrome: what is the optimal fat intake? Am J Med 2002; 113(suppl 9B):25S-9S.
162. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome: the optimal diet. Br J Nutr 2000;83(suppl 1):S143-8.
163. Health Canada. Eating Well With Canada's Food Guide. Ottawa, ON: Health Products and Food Branch, Office of Nutrition and Promotion; 2007. Publication H39-166/1990E. Available at: www.canadasfoodguide.org. Accessed September 16, 2010.
164. Lichtenstein AH, Appel LJ, Brands M, et al; American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006;114:82-96.
165. Kesäniemi A, Riddoch CJ, Reeder B, Blair SN, Sørensen TIA. Advancing the future of physical activity guidelines in Canada: an independent expert panel interpretation of the evidence. Int J Behav Nutr Phys Activ 2010;7:41.
166. Malik VS, Popkin BM, Bray GA, Després J-P, Hu F. Sugar-sweetened beverages, obesity, type 2 diabetes, and cardiovascular risk. Circulation 2010;121:1356-64.
167. Dietitians of Canada. Eating + Activity Tracker. Available at: http://eatracker.ca. Accessed September 15, 2010.
168. Harris SB, Petrella RJ, Lambert-Lanning A, Leadbetter W, Cranston L. Lifestyle management for type 2 diabetes. Are family physicians ready and willing? Can Fam Physician 2004;50:1235-43.
169. Fleming P, Godwin M. Lifestyle interventions in primary care: systematic review of randomized controlled trials. Can Fam Physician 2008;54: 1706-13.
170. Harris SB, Petrella RJ, Leadbetter W. Lifestyle interventions for type 2 diabetes: relevance for clinical practice. Can Fam Physician 2003;49: 1618-25.
171. Lawton BA, Rose SB, Elley CR, Dowell AC, Fenton A, Moyes SA. Exercise on prescription for women aged 40-74 recruited through primary care: two year randomised controlled trial. BMJ 2008;337: a2509.
172. Dale K, McAuley KA, Taylor RW, et al. Determining optimal approaches for successful weight maintenance: a randomized controlled trial. CMAJ 2009;180:E39-46.
173. Isaacs AJ, Critchley JA, Tai SS, et al. Exercise Evaluation Randomised Trial (EXERT): a randomised trial comparing GP referral for leisure centre-based exercise, community-based walking and advice only. Health Technol Assess 2007;11:1-165,iii-iv.
174. Wing RR, Tate DF, Gorin AA, Raynor HA, Fava JL. A self-regulation program for maintenance of weight loss. N Engl J Med 2006;355: 1563-71.
175. Royal D. A systematic review of the effectiveness of nutrition counselling by dietitians in outpatient and in workplace settings. March 2009. Available at: http://www.dietitians.ca/effectiveness. Accessed February 25, 2011.
176. Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610-28.
177. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III), National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-4.
178. Linström J, Louheranta A, Mannelin M, et al; Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.
179. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program. Ann Intern Med 2005;142:611-9.
180. Després J-P, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;322:716-20.
181. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obesity (Lond) 2008;32:619-28.
182. Sharma AM, Douketis JD. Pharmacotherapy for obesity: adults. In: 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176:online 66-71. Available at http://www.cmaj.ca/cgi/data/176/8/S1/DC1/1. Accessed January 30, 2011.
183. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61.
184. Sjöstrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351,2683-93.
185. Drolet B, Simard C, Poirier P. Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs. Am J Cardiovasc Drugs 2007;7:273-88.
186. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a metaanalysis of clinical studies. Diabetes Care 2005;28:942-9.
187. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.NEngl J Med 2010;363:905-17.
188. Food and Drug Administration. Abbott Laboratories agrees to withdraw its obesity drug Meridia [press release]. October 8, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm228812. htm. Accessed January 20, 2011.
189. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic&Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract 2008;14(suppl 1):1-83.
190. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
191. Nguyen NT, Paya M, Stevens CM, Mavandadi S, Zainabadi K, Wilson SE. The relationship between hospital volume and outcome in bariatric surgery at academic medical centers. Ann Surg 2004;240:586-93.
192. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
193. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615-22.
194. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
195. ACCORD Investigators; Gisberg HN, Elam MB, Lovato CC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
196. Keech A, Simes RJ, Barter P, et al; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2006;366:1849-61.
197. BIP Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction (BIP) Study. Circulation 2000;102:21-7.
198. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-8.
199. AIM-High Cholesterol Management Program. Working toward a healthy heart. Available at: http://www.aimhigh-heart.com/background.shtml. Accessed September 16, 2010.
200. H2PS-THRIVE Study. Welcome to the THRIVE study. Available at: http://www.ctsu.ox.ac.uk/=thrive/index.htm. Accessed September 16, 2010.
201. Schwartz GG, Olsson AG, Ballantyne CM, et al; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-901.
202. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991;121:1268-73.
203. ACCORDStudy Group; Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
204. Holman R, Haffner S, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events.NEngl J Med 2010;362: 1463-76.
205. DREAM Trial Investigators, Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008;31:1007-14.
206. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensinconverting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8.
207. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002;288:2981-97.
208. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43: 963-9.
209. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-7.
210. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-13.
211. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
212. McMurray JJ, Holman R, Haffner S, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events.NEngl J Med 2010;362: 1477-90.
213. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
214. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-13.
215. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
216. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531.
217. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396-404.
218. Mottillo S, Filion KB, Belisle P, et al. Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J 2008;30:718-30.
219. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008; 179:135-44.
220. Agency for Health Care Policy and Research. AHCPRSupported Guidelines: clinical interventions for tobacco use and dependence: treating tobacco use and dependence: 2008 update. Washington, DC: National Library of Medicine, 2008.
221. Liu J, Hanley AJ, Young TK, Harris SB, Zinman B. Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada. Int J Obes (Lond) 2006;30:669-76.
222. Anand SS, Yusuf S, Vuksan V, et al; SHARE Investigators. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000;356:279-84.
223. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
224. Deurenberg-Yap M, Chew SK, Deurenberg P. Elevated body fat percentage and cardiovascular risks at low body mass index levels among Singaporean Chinese, Malays and Indians. Obes Rev 2002;3:209-15.
225. Razak F, Anand SS, Shannon H, et al; for the SHARE Investigators. Defining obesity cut points in a multiethnic population. Circulation 2007;115:2111-8.
226. Singh N, Gupta M. Clinical characteristics of South Asian patients hospitalized with heart failure. Ethn Dis 2005;15:615-9.
227. Enas EA, Yusuf S, Mehta J. Meeting of the International Working Group on Coronary Artery Disease in South Asians. 24 March 1996, Orlando, FL, USA. Indian Heart J 1996;48:727-32.
228. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation 2006;113:e924-9.
229. Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular mortality among Canadians of European, South Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ 1999; 161:132-8.
230. Gupta M, Doobay AV, Singh N, et al. Risk factors, hospital management and outcomes after myocardial infarction in South Asian Canadians and matched control subjects. CMAJ 2002;166:717-22.
231. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 2007;297:286-94.
232. Gupta M, Singh N, Warsi M, Reiter M, Ali K. Canadian South Asians have more severe angiographic coronary disease than European Canadians despite having fewer risk factors. Can J Cardiol 2001;17(suppl C): 226C.
233. Brister SJ, Hamdulay Z, Verma S, Maganti M, Buchanan MR. Ethnic diversity: South Asian ethnicity is associated with increased coronary artery bypass grafting mortality. J Thorac Cardiovasc Surg 2007;133: 150-4.
234. Gupta M, Brister S. Is South Asian ethnicity an independent cardiovascular risk factor? Can J Cardiol 2006;22:193-7.
235. Chiu M, Austin PC, Manuel PG, Tu JV. Comparison of cardiovascular risk profiles among ethnic groups using population health surveys between 1996 and 2007. CMAJ 2010;182:E301-10.
236. Leenan FH, Dumais J, McInnis NH, et al. Results of the Ontario Survey on the Prevalence and Control of Hypertension. CMAJ 2008;178:1441-9.
237. Creatore MI, Moineddin R, Booth G, et al. Age- and sex-related prevalence of diabetes mellitus among immigrants to Ontario, Canada. CMAJ 2010;182:781-9.
238. Jafar TH, Chaturvedi N, Pappas G. Prevalence of overweight and obesity and their association with hypertension and diabetes mellitus in an Indo-Asian population. CMAJ 2006;175:1071-7.
239. Mente A, Razk F, Blankenberg S, et al; SHARE, SHARE-AP Investigators. Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care 2010; 33:1629-34.
240. Deurenberg-Yap M, Chew SK, Lin VF, Tan BY, van Staveren WA, Deurenberg P. Relationships between indices of obesity and its morbidities in multi-ethnic Singapore. Int J Obes 2001;25:1554-62.
241. Pan W-H, Flegal KM, Chang H-Y, Yeh W-T, Yeh C-J, Lee W-C. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity in Asians. Am J Clin Nutr 2004;79:31-9.
242. Gu D, Kelly TN, Wu X, et al. Blood pressure and risk of cardiovascular disease in Chinese men and women. Am J Hypertens 2008;21:265-72.
243. Ko GT, Chan JC, Cockram CS, Woo J. Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese. Int J Obes Relat Metab Disord 1999;23: 1136-42.
244. He M, Tan KC, Li ET, Kung AW. Body fat determination by dual energy X-ray absorptiometry and its relation to body mass index and waist circumference in Hong Kong Chinese. Int J Obes Relat Metab Disord 2001;25:748-52.
245. Deurenberg P, Deurenberg-Yap M, Wang J, Lin FP, Schmidt G. The impact of body build on the relationship between body mass index and percent body fat. Int J Obes Relat Metab Disord 1999;23:537-42.
246. Teo KK, Liu L, Chow CK, et al; INTERHEART Investigators in China. Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study. Heart 2009;95:1857-64.
247. Ko GT, So WY, Tong P, et al. Hypoadiponectinaemia enhances waist circumference as a predictor of glucose intolerance and clustering of risk factors in Chinese men. Diabetes Metab 2010;36:192-7.
248. Wang Z, Zhou Q, Fu P, et al. Are the associations of plasma leptin and adiponectin with type 2 diabetes independent of obesity in older Chinese adults? Diabetes Metab Res Rev 2010;26:109-14.
249. Anand SS, Yusuf S, Jacobs R, et al. Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHAREAP). Lancet 2001;358:1147-53.
250. Ley SH, Harris SB, Connelly PW, et al. Adipokines and incident type 2 diabetes in an Aboriginal Canadian population: the Sandy Lake Health and Diabetes Project. Diabetes Care 2008;31:1410-15.
251. Kaler SN, Ralph-Campbell K, Pahar S, King M, Laboucan CR, Toth EL. High rates of the metabolic syndrome in a first nations community in western Canada: prevalence and determinants in adults and children. Int J Circumpolar Health 2006;65:389-402.
252. Harris SB, Zinman B, Hanley A, et al. The impact of diabetes on cardiovascular risk factors and outcomes in a native Canadian population. Diabetes Res Clin Pract 2002;55:165-73.
253. Naqshbandi M, Harris SB, Esler JG, Antwi-Nsiah F. Global complication rates of type 2 diabetes in Indigenous peoples: a comprehensive review. Diabetes Res Clin Pract 2008;82:1-17.
254. Green C, Blanchard J, Young TK, Griffith J. The epidemiology of diabetes in the Manitoba-registered First Nation population: current patterns and comparative trends. Diabetes Care 2003;26:1993-8.
255. Dyck R, Osgood N, Lin TS, Gao A, Stang MR. Epidemiology of diabetes mellitus among First Nations and non-First Nations adults. CMAJ 2010;182:249-56.
256. Harris SB, Gittelsohn, Hanley A, et al. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care 1997;20: 185-7.
257. Harris SB, Naqshbandi M, Hanley AJG, Bhattacharyya OK, Esler JG, Zinman B. Comparison of the clinical management of type 2 diabetes in Canada's First Nations peoples to national guidelines: the CIRCLE study [abstract]. Can J Diabetes 2009;33(3):202.
258. Amed S, Dean HJ, Panagiotopoulos C, et al. Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care 2010;33:786-91.
259. Katzmarzyk PT. Obesity and physical activity among Aboriginal Canadians. Obesity (Silver Spring) 2008;16:184-90.
260. Statistics Canada. Special interest profiles, aboriginal identity, age groups, area of residence, sex and selected demographic, cultural, labour force, educational and income characteristics, for the total population of Canada, Provinces and Territories, 2006 Census of Population. Available at: http://www12.statcan.gc.ca/census-recensement/2006/dp-pd/tbt/Rp-eng.cfm?LANG=E&APATH=3&DETAIL=0&DIM=0&FL=A&FREE=0&GC=0&GID=0&GK=0&GRP=1&PID=97446&PRID=0&PTYPE=88971,97154&S=0&SHOWALL=0&SUB=0&Temporal=2006&THEME=73&VID=0&VNAMEE= &VNAMEF. Accessed September 16, 2010.
261. Health Canada. Ten years of health transfer to First Nations and Inuit control. 1999. Available at: http://www.hc-sc.gc.ca/fniah-spnia/pubs/finance/_agree-accord/10_years_ans_trans/5_agreement-ententeeng. php. Accessed September 16, 2010.
262. Gracey M, King M. Indigenous health part 1: Determinants and disease patterns. Lancet 2009;374:65-75.
263. Anand SS, Razak F, Davis AD, et al. Social disadvantage and cardiovascular disease: development of an index and analysis of age, sex, and ethnicity effects. Int J Epidemiol 2006;35:1239-45.
264. Anderson I, Crengle S, Kamaka ML, Chen TH, Palafox N, Jackson-Pulver L. Indigenous health in Australia, New Zealand, and the Pacific. Lancet 2006;367:1775-85.
265. Martens PJ, Martin BD, O'Neil JD, MacKinnon M. Diabetes and adverse outcomes in a First Nations population: associations with healthcare access, and socioeconomic and geographical factors. Can J Diabetes 2007;31:223-32.
266. Health Canada. Tobacco and the health of Canadians (Health Canada; Canadian Tobacco Use Monitoring Survey). Physicians for a Smoke-free Canada. Available at: http://www.smoke-free.ca/documents/backgroundhealth.htm. Accessed February 26, 2011.
267. Retnakaran R, Hanley AJ, Connelly P, Harris SB, Zinman B. Cigarette smoking and cardiovascular risk factors among Aboriginal Canadian youths. CMAJ 2005;173:885-9.
268. Daniel M, Lekkas P, Cargo M. Environments and cardiometabolic diseases in Aboriginal populations. Heart Lung Circ 2010;19:306-15.
269. Canadian Diabetes Association Clinical Practice Guideline Expert Committee. Type 2 diabetes in high-risk ethnic populations. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(suppl 1): S191-3.
270. Anand SS, Razak F, Yi Q, et al. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004;24:1509-15.
271. McQueen MJ, Hawken S, Wang X, et al; for the INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;19;372:224-33.
272. Grewal J, Anand S, Shofiqul I, Lonn E; for the SHARE and SHARE-AP Investigators. Prevalence and predictors of subclinical atherosclerosis among asymptomatic "low risk" individuals in a multiethnic population. Atherosclerosis 2008;197:435-42.
273. Hux JE, Tang M. Patterns of prevalence and incidence of diabetes. In: Hux JE, Booth GL, Slaughter PM, et al, eds. Diabetes in Ontario. An ICES Practice Atlas. Toronto, ON: Institute for Clinical Evaluative Sciences, 2003:1.1-1.18. Available at: http://www.ices.on.ca/WebBuild/site/ices-internet-upload/file_collection/DM_Chapter1.pdf. Accessed September 16, 2010.
274. Statistics Canada. National population health survey: household component: longitudinal, 1998-1999. Ottawa, ON: Statistics Canada; 2000. Available at: http://www.statcan.gc.ca/cgi-bin/imdb/p2SV.pl?Function=getSurvey&SurvId=3225&SurvVer=0&InstaId=15280&InstaVer=3&SDDS=3225&lang=en&db=imdb&adm=8&dis=2. Accessed September 16, 2010.
275. Physicians for a Smoke-Free Canada. Smoking in Canada: A Statistical Snapshot of Canadian Smokers. Ottawa, ON: Physicians for a Smoke-Free Canada, 2005. Available at: http://www.smoke-free.ca/pdf_1/SmokinginCanada-2005.pdf. Accessed September 16, 2010.
276. Gucciardi E, Vogt JA, DeMelo M, Stewart DE. Exploration of the relationship between household food insecurity and diabetes in Canada. Diabetes Care 2009;32:2218-24.
277. Seligman HK, Laraia BA, Kushel MB. Food insecurity is associated with chronic disease among low-income NHANES participants. J Nutr 2010; 140:304-10.
278. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99: 410-14.
279. FDA Public Health Advisory on Crestor (rosuvastatin). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ PublicHealthAdvisories/ucm051756.htm. Accessed February 25, 2011.
280. Health Canada. Association of CRESTOR (rosuvastatin) with musclerelated adverse events - AstraZeneca Inc. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2005/crestor_2_paap-eng.php. Accessed September 2, 2010.
281. Gupta M, Braga MF, Teoh H, Tsigoulis M, Verma S. Statin effects on LDL and HDL cholesterol in South Asian and white populations. J Clin Pharmacol 2009;49:831-7.
282. Statistics Canada. 2006 census: Ethnic origin, visible minorities, place of work and mode of transportation. Available at: http://www.statcan.gc.ca/daily-quotidien/080402/dq080402a-eng.htm. Accessed September 16, 2010.